The Cambridge Colorectal Cancer Group (CCCG) has broad interests including basic research in colorectal cancer cells and animal models on the cell-biological and molecular mechanisms underpinning the disease. The Group also conducts translational and clinical investigations on prognostic biomarkers, early detection and recurrence of disease, metastasis and cancer therapy. Samples from over 2,000 colorectal cancer patients are being used to create full pathological records and family histories to increase our understanding of the disease.
Current open trials in Cambridge
|Trial name||Trial description||Contact|
|FOCUS 4||FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme||Dr Hugo Ford|
|NSCCG||National Study of Colorectal Cancer Genetics||Dr Cheryl Palmer|
|Quantifying disease burden in patients with cancer using tumour-specific genomic rearrangements||This is a prospective study using human colorectal primary tumour tissue collected at time of surgery,from which we will derive a signature for that patient’s cancer based upon the presence of specific gene rearrangements. The presence of these rearrangements will then for detected for in plasma samples using highly sensitive Q-PCR techniques, and levels will be correlated with progression-free survival and rates of relapse.||Dr Ultan McDermott|
Cambridge Cancer Trials Centre contact for lower gastrointestinal (lower GI) cancer trials: Dr Hugo Ford